Participant‐assessed improvement in rosacea severity ‐ not measured · Participants with ocular rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of participants with adverse event · Participants with ocular rosacea
Ciclosporin ophthalmic emulsion 0.05% showed no clear difference in proportion of participants with adverse event compared with artificial tears (low certainty).
1 finding from 1 review
Physician‐assessed improvement in rosacea severity Schirmer score · Participants with ocular rosacea
1 finding from 1 review
Assessment of erythema or telangiectasia ‐ not measured · Participants with ocular rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Lesion count ‐ not measured · Participants with ocular rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Time needed until improvement of the skin lesions · Participants with ocular rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Duration of remission ‐ not measured · Participants with ocular rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Eating a normally varied diet · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions
The review found no eligible studies for this question.
1 finding from 1 review
Restoration of sexual activity · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions
The review found no eligible studies for this question.
1 finding from 1 review
Reduction in number of flares · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions
The review found no eligible studies for this question.
1 finding from 1 review
Reduction in severity of flares · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions
The review found no eligible studies for this question.
1 finding from 1 review
Ciclosporin · people with chronic plaque psoriasis
It is very uncertain whether any systemic treatment changes ciclosporin compared with placebo (very low certainty).
2 findings from 1 review
Serious adverse events (ciclosporin A) assessed by number of events · psoriatic arthritis
1 finding from 1 review
Withdrawals due to adverse events · psoriatic arthritis
It is very uncertain whether methotrexate changes withdrawals due to adverse events (ciclosporin A) assessed by number… compared with other DMARDs (very low certainty).
1 finding from 1 review
Overall mortality · patients with acquired SAA
First‐line allogeneic hematopoietic stem cell transplantation of… showed no clear difference in overall mortality compared with first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin (low certainty).
1 finding from 1 review
Treatment‐related mortality · patients with acquired SAA
1 finding from 1 review
Health‐related quality of life · patients with acquired SAA
1 finding from 1 review
Graft failure · patients with acquired SAA
1 finding from 1 review
No response to IST · patients with acquired SAA
1 finding from 1 review
Graft‐versus‐host disease · patients with acquired SAA
1 finding from 1 review